Navigation Links
Assured Pharmacy, Inc. Receives Gross Proceeds of $400,000 from Sale of Convertible Debentures and Warrants
Date:8/31/2011

FRISCO, Texas, Aug. 31, 2011 /PRNewswire/ -- Assured Pharmacy, Inc. (Pink Sheets: APHY, the "Company"), a growing chain of specialty pharmacies that provide advanced prescription services to a diverse array of medical professionals and their patients, announced today that it sold in a private placement to an accredited investor a 16.0% (per annum) senior convertible debenture for an aggregate principal amount of $400,000 due December 1, 2012.  The debenture is convertible into 317,460 shares of the Company's common stock at an initial conversion price of $1.26 per share, subject to adjustment.  As part of the private placement, the investor received a warrant to purchase an aggregate of 380,952 shares of the Company's common stock.  The warrant is exercisable for a period of three years from the date of issuance at an initial exercise price of $1.51 per share, subject to adjustment.  The investor may exercise the warrant on a cashless basis if the shares of common stock underlying the warrant have not been registered pursuant to an effective registration statement at the time of exercise.  The funds received from the investor will be directed to the continued development of the Company's business plan and general working capital purposes.  

This financing is supporting the Company's ongoing business expansion and investment into solidifying its supply chain of prescription medications.  "We are very pleased to have the support of this investment as we enter the next phase of our business model," stated Mr. Robert DelVecchio, Chief Executive Officer of Assured Pharmacy.  "As we lay the foundation for expanding our pharmacy footprint into new markets, improving our financial position with suppliers is critical and this financing furthers that requirement."

The securities sold by the Company in the private placement were not registered under the Securities Act of 1933, as amended (the "Securities Act"), and were sold in reliance upon exemptions from the registration requirements of the Securities Act pursuant to Regulation D promulgated under the Securities Act. Therefore, such securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and any applicable state securities laws.

The foregoing information is a summary of the transaction described above, is not complete, and is qualified in its entirety by reference to a more detailed description of the financing and the full text of the agreements, each of which will be available on the OTC Markets website and are available at www.otcmarkets.com under our ticker symbol, APHY.PK. Readers should review the detailed description of the offering along with the agreements for a complete understanding of the terms and conditions associated with this financing transaction.

About Assured Pharmacy, Inc.

Assured Pharmacy, Inc. is engaged in the business of providing specialty pharmacy services to patients and physicians in the treatment of chronic pain. The Company derives its revenue primarily from the sale of highly regulated prescription pain medications and does not keep in inventory non-prescription drugs or health and beauty related products inventoried at traditional pharmacies. The majority of the Company's business is derived from repeat business from its customers. "Walk-in" prescriptions from physicians are limited. The Company currently has four operating pharmacies.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. A wide variety of factors that may cause actual results to differ from the forward-looking statements include, but are not limited to, the following: the Company's ability to increase revenue and profits in the current economic climate; the effect of changing economic conditions; lack of sufficient financing for opening new pharmacies; inability to manage growth; and changes in government regulations, controls and similar matters. These cautionary statements should not be construed as exhaustive or as any admission as to the adequacy of the Company's disclosures. The Company cannot predict or determine after the fact what factors would cause actual results to differ materially from those indicated by the forward-looking statements or other statements. The reader should consider statements that include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", "projects", "should", or other expressions that are predictions of or indicate future events or trends, to be uncertain and forward-looking. The Company does not undertake to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Erika Moran/Adam Holdsworth
The Investor Relations Group
11 Stone St. 3rd Floor
New York, NY
212-825-3210


'/>"/>
SOURCE Assured Pharmacy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Assured Pharmacy Signs Lease in Kansas City, Kansas for its Fifth Pharmacy Location
2. Assured Pharmacy Upgrades to OTC Pink Current Information
3. Assured Pharmacy Engages The Investor Relations Group
4. Assured Pharmacy, Inc. Receives Gross Proceeds of $200,000 from Sale of Convertible Debentures and Warrants
5. Assured Pharmacy Completes Audit of 2010 Financial Statements
6. Assured Pharmacy Announces Reverse Stock Split
7. Assured Pharmacy Reports Same Store Sales for the Month of January 2011
8. Assured Pharmacy Completes Audit of 2008-2009 Financial Statements
9. Assured Pharmacy Reports Same Store Sales for the Month of December 2010
10. Assured Pharmacy, Inc. Receives Gross Proceeds of $300,000 from Sale of Convertible Debentures and Warrants
11. Assured Pharmacy Reports Same Store Sales for the Month of September 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
Breaking Medicine News(10 mins):